Skip to main content

Table 2 Changes in the median (range) blood Phe concentrations (μmol/L) within and between the CGMP-AA2 and Phe-free L-AA group at baseline, 26 and 52 weeks

From: Glycomacropeptide: long-term use and impact on blood phenylalanine, growth and nutritional status in children with PKU

Group

Number of subjects

Baseline μmol/L (range)

Wk 26 μmol/L (range)

Wk 52 μmol/L (range)

P value

CGMP-AA2

29

270 §* (170–430)

300§ (125–485)

300* (200–490)

§p = 0.06 *p = < 0.0011

Phe-free L-AA

19

315 §§** (140–600)

325§§ (180–580)

340** (190–600)

§§P = 0.687 **p = 0.236

  1. Wilcoxon test § GMP baseline to 26 wk., * GMP baseline to 52 wk
  2. Wilcoxon test §§ L-AA baseline to 26 wk., ** L-AA baseline to 52 wk
  3. ABREVIATIONS: CGMP-AA low phenylalanine glycomacropeptide protein substitute supplemented with L-amino acids, Phe-free L-AA Phenylalanine free L-amino acid supplement
Back to article page

Orphanet Journal of Rare Diseases

ISSN: 1750-1172